ArticleChemistry & biodiversity2026
Decoding Ocimum basilicum L.'s Medicinal Potential Through Growth Phase Profiling: A Conservation Perspective.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocimum basilicum L. is widely documented for its medicinal properties, primarily attributed to essential oils (EOs) produced by glandular trichomes on its leaves. The present study investigates how different leaf growth phases lag, log, and stationary affect EO yield and pharmacological activity. Microscopic analysis revealed that trichome density was highest during the lag phase, while trichome size peaked was greatest in the stationary phase. EO yield was greatest in the lag phase (1.26 mL/5 g fresh weight); however, GC-MS profiling indicated that the stationary phase EO contained the highest concentrations of key bioactive compounds, notably eriodictyol and 2,5-dioxoimidazolidin-4-yl urea. Bioactivity assays demonstrated that EO from the log phase exhibited the strongest DPPH radical scavenging activity (63.87 ± 2.95%), whereas the stationary phase EO showed highest total phenolic content (982.61 ± 62.45 mg GAE/g), antioxidant capacity (0.79 ± 0.01 mg EAA/g), anti-inflammatory activity (91.89 ± 10.28%), and antidiabetic potential (95.56 ± 0.00%). Antimicrobial testing confirmed the stationary phase EO as the most potent, with the lowest MIC and MBC values against Staphylococcus aureus (6.25 and 3.125 µL/mL), Ralstonia solanacearum (12.5 and 3.125 µL/mL), and Xanthomonas oryzae (50 and 3.125 µL/mL). These findings suggest that while EO yield is highest in the lag phase, the stationary phase offers the most comprehensive pharmacological potential, making it the optimal harvest stage for medicinal applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.